Dallas, TX -- (SBWIRE) -- 06/05/2015 -- Melanoma of the skin is a malignant neoplasm of melanocytes and is a significant source of morbidity and mortality worldwide.

GlobalData epidemiologists forecast that the diagnosed prevalent cases of melanoma of the skin (all ages) in the 8MM will increase from 155,057 diagnosed prevalent cases in 2013 to 207,606 diagnosed prevalent cases in 2023, at an Annual Growth Rate (AGR) of 3.39%. The forecast shows an increase in the number of diagnosed incident cases of melanoma of the skin in all eight markets with AGRs ranging from 1.37% in Germany to 4.64% in the UK. In 2013, there were 639,165 five-year diagnosed prevalent cases of melanoma of the skin in the 8MM. GlobalData epidemiologists forecast that the five-year diagnosed prevalent cases of melanoma of the skin in the 8MM will increase to 860,889 diagnosed prevalent cases by 2023.

Complete report on Melanoma with 11 market data tables and 8 figures, spread across 51 pages is available at http://www.rnrmarketresearch.com/epicast-report-melanoma-epidemiology-forecast-to-2023-market-report.html .

This forecast is based on a thorough literature review and is supported by 10 years of historical data from IARC's CI-5Plus database. The forecast for melanoma incident rates and diagnosed incident cases was based on detailed age-specific and sex-specific incidence trends in each of the 8MM from the CI-5Plus database published by the IARC of the WHO. GlobalData epidemiologists maintained consistent disease definition and forecasting methodology across all 8MM included in the report. In addition, GlobalData epidemiologists provided a comprehensive review of disease statistics and a realistic trend based on insights gained through research and analysis. GlobalData epidemiologists compared the diagnosed incident case estimates for melanoma from this forecast with the number of estimated incident cases from IARC's GLOBOCAN 2012 to assess the validity of GlobalData's epidemiological forecast and found the two to be in accordance.

Order a purchase copy of this report
http://www.rnrmarketresearch.com/contacts/purchase?rname=389134 . (This is a premium report priced at US$3995 for a single user License.)

Scope

-The Melanoma EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for melanoma of the skin in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma of the skin, segmented by age (in 10-year age groups, beginning at 20 years and ending at =80 years), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] stages I, II, III, and IV). The forecast also includes a 10-year epidemiological forecast for the five-year diagnosed prevalent cases and the five-year diagnosed prevalent cases segmented by genetic aberrations (BRAF and c-KIT) in these markets.

-The melanoma epidemiology report is written and developed by Mastersand PhD-level epidemiologists.

-The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

-Develop business strategies by understanding the trends shaping and driving the global melanoma market.

-Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.

-Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for melanoma therapeutics in each of the markets covered.

Explore more reports on cancer therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics .

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.